Applied Biosystems — Applera — The Third Annual Piper Jaffray Europe Conference 2008
25 slides from Applied Biosystems's conference presentation, Jun 25, 2008

Slide 1: The Third Annual Piper Jaffray Europe Conference
Piper Jaffray June 2008 24-25, Applied Biosystems Industry expertise: Business Services - Clean technology - Consumer - Financial Institutions - Health Care - Industiral Growth - Technology The Third Annual Piper Jaffray Europe Conference

Slide 2: Piper Jaffray Europe Conference
Piper Jaffray Europe Conference Peter Dworkin Vice President, Investor Relations & Corp. Communications Applera Corporation June 25, 2008

Slide 3: Safe Harbor Statement
Piper Jaffray June 2008 3 Safe Harbor Statement Statements presented which are not historical facts, including, but not limited to, those relating to revenue growth, financial targets, product and marketing prospects, and product demand, are forward looking statements and are subject to a variety of

Slide 4: Forward-looking statements
Piper Jaffray June 2008 4 Certain statements contained in this presentations are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and Invitrogen and Applera intend that such forward-looking statements be subject to the safe harbor created there

Slide 5: Non-GAAP Measurements and Additional Information
Piper Jaffray June 2008 5 Non-GAAP Measurements This presentation and discussion includes certain financial information which constitute “non-GAAP financial measures” as defined by the SEC. The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these m

Slide 6: Applied Biosystems Company Overview/Highlights
Piper Jaffray June 2008 6 Applied Biosystems Company Overview/Highlights • ABI (NYSE) is a global leader in supplying the life science industry with advanced technology; founded in 1981; ~5,000 employees; HQ in Foster City, CA, USA; FY07 revenue $2.1bn • Serving research, pharmaceutical, and applied

Slide 7: Gaining Financial Momentum (Non-GAAP performance)
May 2008 © 2008 Applied Biosystems 7 Gaining Financial Momentum (Non-GAAP performance) 53.3% 54.7% 15.4% 16.5% $1.06 $1.24 $1.79B $1.91B * Operating Margin and non-GAAP EPS exclude special items. GAAP reconciliations can be found at www.appliedbiosystems.com in the Financial Reports page of the Inve

Slide 8: Revenue Mix
8 Piper Jaffray June 2008 Revenue Mix 43% 40% 17% 25% 42% 18% 40% Consumables Instruments Other YTD FY 08 Business Mix YTD % chg vs. prior year Instruments -1.5% Consumables 10.2% Other 9.5% Total 5.2% • 59% of YTD FY08 revenues recognized outside of the United States • Revenue reported in 5 product

Slide 9: SOLiD System Advances
9 Piper Jaffray June 2008 SOLiDTM System Advances • SOLiD 2.0 Now Shipping – Early access customers achieving >13Gb runs – Can detect and map inserts ranging from 600bp-10Kb – More accurate and robust than SOLiD 1.0 • Delivering Key Project Performance – 1000 Genomes Project (Baylor & BGI) – Cancer

Slide 10: Sequencing Continuum – Next Generation Technologies Are Expanding the Market
10 Piper Jaffray June 2008 Research (CE) -7.2% Research (NGS) 35.1% Commercial (CE) 9.5% Source: L.E.K. Consulting and AB Internal Sequencing Continuum – Next Generation Technologies Are Expanding the Market • High volume research segments are beginning to utilize NGS technologies • CE will continue

Slide 11: Building from a Strong Market Presence in Mass Spec
11 Piper Jaffray June 2008 Addressable Market Market Trends Strategy Building from a Strong Market Presence in Mass Spec Products / Markets Applications •Biomarker discovery and validation •Proteomics •Protein ID and Characterization •Drug Metabolism & ADME-Tox •Protein purification • Disease Resear

Slide 12: Creating the Premier Provider of Biotechnology Reagents and Systems
12 Piper Jaffray June 2008 Creating the Premier Provider of Biotechnology Reagents and Systems Definitive Merger Agreement Announced June 12, 2008

Slide 13: Combining Industry Leaders
13 Piper Jaffray June 2008 Combining Industry Leaders • Founded: 1987 • Premier provider of consumable kits and reagents • Annual revenue of $1.3 billion • Leading positions in: – Cell Culture (GIBCO) – Labeling and Detection – Molecular Biology Kits • ~4,700 employees • 1,200 patents & licenses • C

Slide 14: Transaction Overview
14 Piper Jaffray June 2008 Transaction Overview Transaction Structure Consideration and Relative Ownership Approvals Company Name Headquarters Closing • Invitrogen will acquire all of the outstanding shares of Applied Biosystems for $38 per share in a combination of cash and stock, for a total value

Slide 15: Transaction Overview (Continued): Board Composition and Executive Management
15 Piper Jaffray June 2008 Board Composition Executive Management • 9 Invitrogen and 3 Applera board members Greg Lucier Chairman and CEO • Invitrogen CEO and Board Member since May 2003 • Invitrogen Chairman since April 2004 • Former Corporate Officer of General Electric Corporation David Hoffmeist

Slide 16: Newco Competitive Advantages
16 Piper Jaffray June 2008 Newco Competitive Advantages New Company Well-Positioned to Benefit From Macrotrends Genomics and cell biology convergence Translation of technologies to applied markets Race to understand human genome and genetic variations Growth in emerging geographies Positioned to cap

Slide 17: Strategic Rationale
17 Piper Jaffray June 2008 • Highly complementary, best-in-class product offerings • Broad and extensive commercial network • Strong platform for expansion into high-growth markets • Significant value creation opportunities for shareholders • Strong financial profile Strategic Rationale Merger combi

Slide 18: With Highly Complementary Revenue Streams
18 Piper Jaffray June 2008 ...With Highly Complementary Revenue Streams Consumables & Services* 60% Mass Spec Instruments 19% Instrument Reagent Systems 21% Consumables & Services* 74% Mass Spec Instruments 12% Instrument Reagent Systems 14% Consumables & Services* 99% Instrument Reagent Systems 1%

Slide 19: Broad and Extensive Commercial Network with Complementary Skills
19 Piper Jaffray June 2008 • Excels at repeat business • e-Commerce expertise • 1,000+ supply centers • Strong relationships with bench scientists • Excels at systems sales • Global service infrastructure • Presence beyond life sciences • High level customer relationships • Approximately 3,000 sales

Slide 20: Strong Platform for Expansion Into High Growth Markets
20 Piper Jaffray June 2008 Market Size Market Growth Capabilities: Applied Markets $9B Low double digits Emerging Geographies $1B Midteen’s Cell Biology $6B High single digits Next Gen Sequencing >35% $200M Strong Platform for Expansion Into High Growth Markets

Slide 21: Significant Opportunities for Value Creation
21 Piper Jaffray June 2008 • At least $125 million annual cost savings by 3rd year – Raw material synergies – Overhead redundancies – Facility rationalization – R&D scale • At least $50 million annual Operating Income from revenue synergies by 3rd year – Cross selling/channel synergies – Penetration

Slide 22: Strong Financial Profile
22 Piper Jaffray June 2008 • ~$3.5 billion in combined LTM revenue • Strong EBITDA and operating cash flow contribution • Intent to quickly repay debt LTM March 31, 2008 $803 23% $480 22% $323 24% Operating Cash Flow as % of Revenue $859 25% $490 23% $369 28% EBITDA(1) as % of Revenue $3,496 $2,173

Slide 23: Revenue Diversified Across Segments
23 Piper Jaffray June 2008 Revenue Diversified Across Segments... ...with a significant contribution from high-margin consumables Rev. By End Markets Rev. By Product Mix Industry & Other 20% Pharma & Biotech 30% Academic & Govt 50% Rev. By Geography United States 44% Europe 34% APAC 16% Other 6% Con

Slide 24: Strategic Rationale
24 Piper Jaffray June 2008 • Highly complementary, best-in-class product offerings • Broad and extensive commercial network • Strong platform for expansion into high-growth markets • Significant opportunities for value creation for shareholders • Strong financial profile Strategic Rationale Merger c

Slide 25: Forward Looking Statements
25 Piper Jaffray June 2008 24-25, Applied Biosystems Industry Expertise: Business Services - Clean Technology - Consumer - Financial Institutions - Health Care - Industrial Growth - Technology The Third Annual Guides For the Journey - Piper Jaffray * * * FORWARD LOOKING STATEMENTS Some statements ma
Source: SEC EDGAR · DEFA14A filed Jun 25, 2008


